As a result, all major public health organizations in the US and globally now recommend treatment for all people living with HIV, no matter their CD4 count.

The lower your viral load, the less active HIV is and the more likely you are to have a healthy immune system. One way to find out if your immune system is damaged is to have a CD4 cell count done. This is a routine blood test. If you have fewer than CD4 cells you are at greater risk for opportunistic infections, and your health care provider will probably recommend that you get medications that prevent certain OIs.

An increase in the number of CD4 cells is one sign that your immune system is getting stronger. At first, the new CD4 cells are probably copies of existing types of CD4 cells.

If some types of CD4 cells were lost, they may not come back right away. This could leave some gaps in the body's immune defenses.

However, if HIV stays under control for a few years, the immune system may make new types of CD4 cells that can fill in these gaps and more completely restore immune function. A viral load test tells you how active HIV is in your body. When compared over time, viral load test results show if the amount of HIV in your bloodstream is higher or lower than it was before.

When a combination of HIV drugs your drug regimen is working, the viral load usually goes down within weeks of starting the drugs, ideally to undetectable within several months. One goal of HIV treatment is to keep viral loads as low as possible for as long as possible.

Although an increase in CD4 cells and a decrease in viral load are usually good signs, certain types of infections may flare up or HIV-related symptoms may get worse in some people. This is referred to as immune reconstitution inflammatory syndrome IRIS.

IRIS can also worsen some other conditions, especially autoimmune problems. IRIS happens when your immune system acts so strongly and so quickly that it causes a strong inflammation, which actually makes your symptoms worse. For most, these symptoms include fever, swollen lymph glands, and rash, and they go away in a few weeks.

For others, the symptoms are more severe, and they should tell their health care provider. The symptoms often depend on the germs already in your body when the immune system began its strong, inflammatory response.

You may or may not know that you have these infections. They may only be diagnosed when related symptoms occur because of the new and improved immune response. The following infections often flare up: Mycobacterium avium complex MAC , cytomegalovirus CMV , herpes simplex virus HSV , hepatitis B and C , tuberculosis TB , herpes zoster or shingles , Kaposi sarcoma KS , and PCP pneumocystis pneumonia.

IRIS can also worsen some other conditions, especially autoimmune problems like Graves' disease, lupus, or rheumatoid arthritis.

It is important to share any new symptoms with your doctor. IRIS usually occurs in the first six weeks of treatment. It can occur in anyone starting HIV drugs for the first time, starting HIV drugs after being off them for a while, or switching to new HIV drugs.

Most cases of IRIS occur in people who have very low CD4 counts and high viral loads when they begin or switch HIV drugs, but IRIS can occur at any CD4 count. You can prevent IRIS, if you begin taking HIV drugs as soon as you are diagnosed with HIV.

Although the outlook for most people living with HIV who have IRIS is good, the syndrome has been associated with some serious illnesses. Here, we explore different examples of therapeutic modulations of intra-lineage plasticity, for both macrophages and neutrophils.

In certain conditions, accelerating tissue repair could be decisive, particularly for certain wounds such as large or life-threatening wounds and for certain patients such as elderly or fragile patients. Remarkably, patients treated by immunosuppressive therapy experience a delayed wound healing, which shows that the inflammatory stage is important to induce repair.

The complexity of tissue repair is due to the number of involved partners but also to the precise timing and imbrication of the phases. Therefore, isolating new targets, even of great importance, will not be sufficient if the whole balance and timing are not considered.

Numerous mediators involved in the phenotype conversion of macrophages have been described, but so far their therapeutic potential remains uncertain in humans Reparative neutrophils could also be modulated to accelerate the process of wound healing In cardiac infarction, a temporal switch from inflammatory to resolving neutrophils has been detected Programming neutrophils to the N2 subtype by a PPARγ agonist rosiglitazone could be used to obtain a beneficial role of anti-inflammatory N2 neutrophils, as shown in stroke A chronic wound could be seen as resulting from a dysregulated repair process, with an increase of pro-inflammatory environment at the expense of the pro-resolving one Figure 2.

Modulating cell plasticity toward a more resolving phenotype appears an attractive strategy in that line. Figure 2. Relative importance of inflammation, new tissue formation, and remodeling in three different situations.

In normal wound healing, inflammation 1, in red , new tissue formation 2, in green , and remodeling 3, in purple are at a basal level. In ulcers, inflammation and new tissue formation are at higher levels, whereas remodeling is lower than the basal level.

In fibrosis, inflammation, new tissue formation, and remodeling are all higher than their basal levels. Mechanical debridement of a chronic wound consists in the removal of dead tissues to improve the healing potential of the remaining healthy tissue.

This removal leads to tissue re-colonization by immune cells, suggesting that they are important in the repair process. Maggot therapy could empirically modulate immune cell plasticity in addition to its mechanical role.

Some data indicate that maggot secretions decrease the elastase release and the H 2 O 2 production of activated neutrophils without affecting their phagocytic activity Moreover, maggot secretions inhibit the production of pro-inflammatory cytokines by monocytes, skewing their phenotype from a pro-inflammatory to a pro-angiogenic type Another approach is to figure out the exact cause of the chronic pro-inflammatory stimulation and develop a therapeutic strategy specific to this cause.

In some cases, the pro-inflammatory stimulation is associated with bacterial biofilms 93 — Biofilms in acute surgical and chronic wounds appear to cause a delay in healing In this composite state, bacteria are resistant against antibiotic treatment and immune responses, leading to impaired eradication of opportunistic pathogens.

Biofilm-embedded bacteria release virulence factors dictated by quorum-sensing that in turn promote inflammatory mediators such as IL-1β, contributing to delayed wound re-epithelialization and healing 96 , Hence, dealing with biofilms has become a major challenge in chronic wound healing.

Quorum-sensing blockers could be an innovative approach to treat non-healing wounds, even though clinical trials are needed to prove their relevance Keloid and hypertrophic scars are pathologic fibroproliferative disorders characterized by an excess of collagen deposition in genetically predisposed patients.

In hypertrophic scars, inflammatory genes are expressed at a lower level and for a longer time, with a delayed but prolonged infiltration of M2 macrophages Hypertrophic scar development is dependent on macrophages as their depletion during the subacute phase allows normal scarring in mice Thus, limiting M2 activation in keloid could be a way to circumvent the hypertrophic scar.

Diffuse cutaneous systemic sclerosis dcSSc is a form of over-repair. SSc results from the interaction of three processes: innate and adaptive immune abnormalities, vasculopathy, and fibroblast dysfunction leading to excessive collagen and matrix components accumulation Fibrotic skin is characterized by an immune cell infiltrate of various nature 15 , — These cells follow a chemokine gradient, such as CCL2, partly explaining the recruitment of macrophages and the M2 polarization in SSc skin , Limiting M2 activation and even activating M1 could be an interesting lead for dcSSc at the proper stage.

The window of opportunity is critical, and studies showing the evolution of cell plasticity during SSc evolution are lacking to establish reliable therapy based on cell plasticity.

Nevertheless one can assume that the number of pro-inflammatory innate cells is limited to a first phase, and then a pro-reparative profile of cells is predominant, giving a place for anti-resolving cell drugs. At the last stage, the absence of infiltrating cells could prevent the efficiency of immunological approaches.

Immunologists have tended to see the immune system as a system of defense. By constantly surveying the body and responding to anomalies and through its pleiotropic roles in defense, development, and repair, the immune system is pivotal for the robustness of the organism 6. Robustness does not mean an absence of change: quite the contrary, it is through constant internal modifications that an organism can maintain its functions.

We should therefore not be surprised by the main conclusion of the present review, which is that immune cell plasticity [and cell plasticity more generally 65 , ] is essential to ensure the robustness of the organism as far as tissue repair is concerned.

Though still in its infancy, the idea of therapeutically manipulating immune cell plasticity in repair seems extremely promising. We have examined several examples where the manipulation of immune cell plasticity is already a reality, and we can only look forward to future investigations.

Crucially, the immune system plays a key role in repair and regeneration across species, and regeneration is often associated with an immunosuppressive state — Successful regeneration also presupposes cell plasticity, both intra-lineage and trans-lineage , It is exciting to speculate that immune cell plasticity could play an important role in regeneration and that one day clinicians could manipulate this immune plasticity to skew the balance between damaging and reparative effects toward the desirable state for any given patient.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. We would like to thank Patrick Blanco, Julie Déchanet-Merville, Gérard Eberl, and Jean-François Moreau for comments on this work.

Bernard C. Lectures on the Phenomena of Life Common to Animals and Plants. Springfield, IL: Thomas Google Scholar. Csete ME, Doyle JC. Reverse engineering of biological complexity. Science —9. doi: PubMed Abstract CrossRef Full Text Google Scholar.

Kitano H. Biological robustness. Nat Rev Genet — Stelling J, Sauer U, Szallasi Z, Doyle FJ, Doyle J. Robustness of cellular functions.

Cell — Cannon WB. Organization for physiological homeostasis. Physiol Rev — Kourilsky P. The natural defense system and the normative self model. FRes Pradeu T.

The Limits of the Self: Immunology and Biological Identity. New York, NY: Oxford University Press Gurtner GC, Werner S, Barrandon Y, Longaker MT.

Wound repair and regeneration. Nature — Eming SA, Martin P, Tomic-Canic M. Wound repair and regeneration: mechanisms, signaling, and translation.

Sci Transl Med sr6. Cordeiro JV, Jacinto A. The role of transcription-independent damage signals in the initiation of epithelial wound healing.

Nat Rev Mol Cell Biol — CrossRef Full Text Google Scholar. Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, et al.

An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell — Karin M, Clevers H. Reparative inflammation takes charge of tissue regeneration.

White ES, Mantovani AR. Inflammation, wound repair, and fibrosis: reassessing the spectrum of tissue injury and resolution.

J Pathol —4. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med — Chizzolini C, Brembilla NC, Montanari E, Truchetet M-E. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev — Longaker MT, Gurtner GC.

Introduction: wound repair. Semin Cell Dev Biol Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med —9. Tumors: wounds that do not heal — redux. Cancer Immunol Res — Chovatiya R, Medzhitov R.

Stress, inflammation, and defense of homeostasis. Mol Cell —8. Clark WR. In Defense of Self: How the Immune System Really Works. Oxford; New York, NY: Oxford University Press Criscitiello MF, de Figueiredo P.

Fifty shades of immune defense. PLoS Pathog 9:e Janeway CA. How the immune system protects the host from infection. Microbes Infect — Lemaitre B, Hoffmann J. The host defense of Drosophila melanogaster. Annu Rev Immunol — Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al.

A special population of regulatory T cells potentiates muscle repair. Leoni G, Neumann P-A, Sumagin R, Denning TL, Nusrat A. Wound repair: role of immune-epithelial interactions. Mucosal Immunol — Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis.

Immunity — Barbul A. Immune aspects of wound repair. Clin Plast Surg — PubMed Abstract Google Scholar. DiPietro LA. Wound healing: the role of the macrophage and other immune cells. Shock — Park JE, Barbul A. Understanding the role of immune regulation in wound healing.

Am J Surg S—6S. Stramer BM, Mori R, Martin P. The inflammation-fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. J Invest Dermatol — Galliot B, Crescenzi M, Jacinto A, Tajbakhsh S.

Trends in tissue repair and regeneration. Development — Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol — Chang-Panesso M, Humphreys BD.

To illustrate the problems associated with assessing overall immunity let us consider the example of blood pressure management. Specific target values under treatment have been also personalized [ 67 ]. No such scheme currently exists for the immune system. The assessment of an individual immune responsiveness by confronting the immune system with common or new vaccine antigens and hence quantifying the quality of the immune functioning in its whole is a desirable challenge.

This approach was used successfully in the rapalogue trials [ 28 ], but has the drawback that large numbers of individuals have to be recruited for each arm to ensure statistically significant results are achieved. Longitudinal studies in which the same individual is followed and tested before and after treatment may appear more preferable but has the problem in that if vaccination is used as an assay system it would have to be given before and the after the treatment.

This may prove a problem especially when the repeat vaccination is against previously used strains because high pre-vaccination hemagglutination antibody inhibition titres because the history of previously encountered influenza subtypes impacts the ensuing immune response [ 69 , 70 , 71 ]. Equally well, with other vaccines such as pneumococcal polysaccharides vaccines subsequent repetitive vaccination would fail to show benefit because of the hyporesponsiveness [ 72 ] seen on revaccination.

Another option is to choose to issue the participants with illness diaries which monitor the number of infections during the period of the study and also their duration [ 73 ]. Compliance is often a factor with this approach as is veracity. Subjective assessment whilst sometimes necessary may not be optimal which is why many have chosen a more objective approach and taken to using indirect methods of assessment.

Clinicians can have access to a large battery of biological tests. They include complete blood counts, lymphocyte subsets, serum immunoglobulin levels and the presence of specific antibodies, none of which could be used to assess immune rejuvenation satisfactorily.

This is principally because these values can be similar in individuals who are immune competent and those who provide a less than adequate response.

Approaches to identifying improvements in global immunity have included measuring change in the numbers of recent thymic emigrants [ 51 ], the presence of increased numbers of naïve lymphocytes or changes in subsets cells at different stages of differentiation [ 74 ], cutaneous skin responses [ 75 ] or changes in the parameters [ 76 ] of the immune risk phenotype [ 77 ].

The issue at the core of the question about whether we can rejuvenate the immune response is one of measurement. We currently have no method of measuring the overall immune capacity of an individual. Often this measure is through clinical observation that the patient has infections which are unusual, persistent, or alternatively which have become recurrent or have progressed to becoming systemic.

These are often subjective assessments and there are no objective laboratory based tests which provide a measure of overall immune capacity. This despite a long history of assays which quantify a response to an antigen through demonstrating the antibody titre or assessing an individual T cell specific response to a viral glycoprotein.

We only know the level of response associated with protection from a disease for a small handful of pathogens. There is no normal range for immune activity and until we can provide a method for measuring this activity we have firstly no means of determining whether an individual is in need of therapy and secondly what the effect of that rejuvenation therapy may be.

The complexity of the problem is also added to by the identification that a successful immune response is not only dependant on producing enough specific antibody of effector T cells.

Susceptibility to disease is also reliant on a number of innate immune system barriers, such as the integrity of the skin, the flushing action of tears, saliva or urine, the action of ciliated epithelium and mucous as well as the response from neutrophils, macrophages and natural killer cells.

Fulop T, et al. Aging, frailty and age-related diseases. Article CAS PubMed Google Scholar. Lang PO, Mitchell WA, Lapenna A, Pitts D, Aspinall R. Immunological pathogenesis of main aged-related disease and frailty: role of immunosenescence.

Eur Geriatric Med. Article Google Scholar. Cliff A, Haggett P. Time, travel and infection. Br Med Bull. Article PubMed Google Scholar. Lang, P.

Chikungunya Virus Infection: Why Should U. Geriatricians Be Aware of It? J Am Geriatr Soc. Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Aspinall R, Lang PO. Vaccination choices for older people, looking beyond age specific approaches.

Expert Rev Vaccines. Lang PO, Trivalle C, Vogel T, Proust J, Papazian JP. Markers of metabolic and cardiovascular health in adults: comparative analysis of DEXA-based body composition components and BMI categories. J Cardiol. Lang PO, et al. Is obesity a marker of robustness in vulnerable hospitalized aged populations?

Prospective, multicenter cohort study of 1 acutely ill patients. J Nutr Health Aging. Dixit VD. Thymic fatness and approaches to enhance thymopoietic fitness in aging. Curr Opin Immunol. Article CAS PubMed Central PubMed Google Scholar. Yang H, et al. Obesity accelerates thymic aging.

Yang H, Youm YH, Dixit VD. Inhibition of thymic adipogenesis by caloric restriction is coupled with reduction in age-related thymic involution. J Immunol. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol.

Bharath LP, Ip BC, Nikolajczyk BS. Adaptive immunity and metabolic health: harmony becomes dissonant in obesity and aging. Compr Physiol. Choi CHJ, Cohen P. Adipose crosstalk with other cell types in health and disease. Exp Cell Res. Calder PC, et al.

Health relevance of the modification of low grade inflammation in ageing inflammageing and the role of nutrition. Ageing Res Rev. Johnson MO, Siska PJ, Contreras DC, Rathmell JC. Nutrients and the microenvironment to feed a T cell army.

Semin Immunol. Seman K, Abdul Manaf H, Ismail AR. Arch Orofac Sci. Langkamp-Henken B, et al. Nutritional formula improved immune profiles of seniors living in nursing homes. Akatsu H, et al. Enhanced vaccination effect against influenza by prebiotics in elderly patients receiving enteral nutrition.

Geriatr Gerontol Int. Vidal K, et al. Immunomodulatory effects of dietary supplementation with a milk-based wolfberry formulation in healthy elderly: a randomized, double-blind, placebo-controlled trial.

Rejuvenation Res. Girodon F, et al. Impact of trace elements and vitamin supplementation on immunity and infections in institutionalized elderly patients: a randomized controlled trial.

MIN VIT AOX Geriatr Netw Arch Intern Med. Article CAS Google Scholar. Freeman SL, et al. Dairy proteins and the response to pneumovax in senior citizens: a randomized, double-blind, placebo-controlled pilot study.

Ann N Y Acad Sci. Moriguti JC, Ferriolli E, Donadi EA, Marchini JS. Effects of arginine supplementation on the humoral and innate immune response of older people. Eur J Clin Nutr. Pae M, Meydani SN, Wu D. The role of nutrition in enhancing immunity in aging. Aging Dis. PubMed Google Scholar.

Braga CB, et al. Effect of zinc supplementation on serological response to vaccination against streptococcus Pneumoniae in patients undergoing chemotherapy for colorectal cancer. Nutr Cancer. Lang PO, Aspinall R. Vitamin D status and the host resistance to infections: what it is currently not understood.

Clin Ther. Keating R, et al. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol. Mannick, J. et al. mTOR inhibition improves immune function in the elderly. Lefebvre JS, Haynes L.

Vaccine strategies to enhance immune responses in the aged. Cunningham AL, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons.

Stowe RP, et al. Chronic herpesvirus reactivation occurs in aging. Exp Gerontol. Cobbold M, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. Neuenhahn, M. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.

Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U. Dave H, et al. Toward a rapid production of multivirus-specific T cells targeting BKV, adenovirus, CMV, and EBV from umbilical cord blood.

Mol Ther Methods Clin Dev. Loffredo FS, et al. Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Villeda SA, et al. Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med. Davies J, Pulko V, Thompson H, Nikolich-Zugich J.

Chronic parabiosis: allowing the dissection of the aged immune system. Pishel I, et al. Accelerated aging versus rejuvenation of the immune system in heterochronic parabiosis. Huestis D, Alexander W.

Bogdanov: the forgotten pioneer of blood transfusion. Transfus Med Rev. Aspinall R, Govind S, Lapenna A, Lang PO. Dose response kinetics of CD8 lymphocytes from young animals transfused into old animals and challenged with influenza.

Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Andrew D, Aspinall R. Il-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice.

Muegge K, Vila MP, Durum SK. Interleukin a cofactor for V D J rearrangement of the T cell receptor beta gene. Lundstrom W, Fewkes NM, Mackall CL. IL-7 in human health and disease. Article PubMed Central PubMed Google Scholar. Fry TJ, Mackall CL.

The many faces of IL from lymphopoiesis to peripheral T cell maintenance. Bhatia SK, Tygrett LT, Grabstein KH, Waldschmidt TJ. The effect of in vivo IL-7 deprivation on T cell maturation. Henson SM, Snelgrove R, Hussell T, Wells DJ, Aspinall R. An IL-7 fusion protein that shows increased thymopoietic ability.

El Kassar N, et al. A dose effect of IL-7 on thymocyte development. El-Kassar N, et al. High levels of IL-7 cause dysregulation of thymocyte development. Int Immunol.

Do combination antiretroviral therapy regimens for HIV infection feature diverse T-cell phenotypes and inflammatory profiles? Open Forum Infect Dis 7 9 :ofaa Prendergast AJ, Szubert AJ, Pimundu G, Berejena C, Pala P, Shonhai A, et al.

AIDS 35 10 — Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.

Ji Y, Zhang F, Zhang R, Shen Y, Liu L, Wang J, et al. Emerg Microbes Infect 7 1 Nowak P, Troseid M, Avershina E, Barqasho B, Neogi U, Holm K, et al. Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS 29 18 — Lee SC, Chua LL, Yap SH, Khang TF, Leng CY, Raja Azwa RI, et al. Enrichment of gut-derived fusobacterium is associated with suboptimal immune recovery in HIV-infected individuals.

Sci Rep 8 1 Lu D, Zhang JB, Wang YX, Geng ST, Zhang Z, Xu Y, et al. BMC Infect Dis 21 1 Lu W, Feng Y, Jing F, Han Y, Lyu N, Liu F, et al. Association between gut microbiota and CD4 recovery in HIV-1 infected patients.

Front Microbiol Wherry EJ. T Cell exhaustion. Nat Immunol 12 6 —9. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression.

Nature —4. Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, et al. T-Cell exhaustion in HIV infection. Immunol Rev 1 — Wang S, Zhang Q, Hui H, Agrawal K, Karris MAY, Rana TM.

An atlas of immune cell exhaustion in HIV-infected individuals revealed by single-cell transcriptomics. Emerg Microbes Infect 9 1 — Noyan K, Nguyen S, Betts MR, Sönnerborg A, Buggert M.

Chen H, Moussa M, Catalfamo M. The role of immunomodulatory receptors in the pathogenesis of HIV infection: a therapeutic opportunity for HIV cure? Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, et al. Nat Immunol 8 11 — Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA, et al.

Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood 4 — Banga R, Procopio FA, Noto A, Pollakis G, Cavassini M, Ohmiti K, et al. Nat Med 22 7 — McGary CS, Deleage C, Harper J, Micci L, Ribeiro SP, Paganini S, et al.

Immunity 47 4 — Tian X, Zhang A, Qiu C, Wang W, Yang Y, Qiu C, et al. The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects. J Immunol 8 — Cockerham LR, Jain V, Sinclair E, Glidden DV, Hartogenesis W, Hatano H, et al.

AIDS 28 12 — Grabmeier-Pfistershammer K, Steinberger P, Rieger A, Leitner J, Kohrgruber N. Identification of PD-1 as a unique marker for failing immune reconstitution in HIVinfected patients on treatment. J Acquir Immune Defic Syndr 56 2 — Nakanjako D, Ssewanyana I, Mayanja-Kizza H, Kiragga A, Colebunders R, Manabe YC, et al.

High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort.

BMC Infect Dis Antoine P, Olislagers V, Huygens A, Lecomte S, Liesnard C, Donner C, et al. J Immunol 5 — Crawford A, Angelosanto JM, Kao C, Doering TA, Odorizzi PM, Barnett BE, et al. Immunity 40 2 — Ji Y, Dang X, Nguyen LNT, Nguyen LN, Zhao J, Cao D, et al.

Topological DNA damage, telomere attrition and T cell senescence during chronic viral infections. Immun Ageing Cobos Jiménez V, Wit FW, Joerink M, Maurer I, Harskamp AM, Schouten J, et al. T-Cell activation independently associates with immune senescence in HIV-infected recipients of long-term antiretroviral treatment.

Deeks SG, Verdin E, McCune JM. Immunosenescence and HIV. Curr Opin Immunol 24 4 —6. Sokoya T, Steel HC, Nieuwoudt M, Rossouw TM. HIV As a cause of immune activation and immunosenescence. Mediators Inflammation Gratz IK, Rosenblum MD, Abbas AK. The life of regulatory T cells.

Ann N Y Acad Sci — Schumacher A, Zenclussen AC. Regulatory T cells: regulators of life. Am J Reprod Immunol 72 2 — Sakaguchi S, Yamaguchi T, Nomura T, Ono M.

Regulatory T cells and immune tolerance. Cell 5 — Shevach EM. Immunity 30 5 — Sakaguchi S, Miyara M, Costantino CM, Hafler DA. Nat Rev Immunol 10 7 — Card CM, McLaren PJ, Wachihi C, Kimani J, Plummer FA, Fowke KR. J Infect Dis 9 — Chevalier MF, Weiss L. The split personality of regulatory T cells in HIV infection.

Blood 1 — Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. Blood 10 — Kinter A, McNally J, Riggin L, Jackson R, Roby G, Fauci AS.

Proc Natl Acad Sci U. Estes JD, Wietgrefe S, Schacker T, Southern P, Beilman G, Reilly C, et al. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection.

Shaw JM, Hunt PW, Critchfield JW, McConnell DH, Garcia JC, Pollard RB, et al. Increased frequency of regulatory T cells accompanies increased immune activation in rectal mucosae of HIV-positive noncontrollers.

J Virol 85 21 — Saison J, Maucort Boulch D, Chidiac C, Demaret J, Malcus C, Cotte L, et al. Open Forum Infect Dis 2 2 :ofv Nobrega C, Horta A, Coutinho-Teixeira V, Martins-Ribeiro A, Baldaia A, Rb-Silva R, et al. Longitudinal evaluation of regulatory T-cell dynamics on HIV-infected individuals during the first 2 years of therapy.

AIDS 30 8 — Deng K, Pertea M, Rongvaux A, Wang L, Durand CM, Ghiaur G, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature —5. Cartwright EK, Spicer L, Smith SA, Lee D, Fast R, Paganini S, et al. Immunity 45 3 — Fan J, Liang H, Ji X, Wang S, Xue J, Li D, et al.

CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques. Nat Commun 10 1 Zhang LX, Jiao YM, Zhang C, Song JW, Fan X, Xu RN, et al. HIV Reservoir decay and CD4 recovery associated with high CD8 counts in immune restored patients on long-term ART.

Cao W, Mehraj V, Kaufmann DE, Li T, Routy JP. Elevation and persistence of CD8 T-cells in HIV infection: the achilles heel in the ART era. J Int AIDS Soc 19 1 Ananworanich J, Fletcher JL, Pinyakorn S, van Griensven F, Vandergeeten C, Schuetz A, et al.

A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, et al.

Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. Chen J, Xun J, Yang J, Ji Y, Liu L, Qi T, et al. Plasma indoleamine 2,3-dioxygenase activity is associated with the size of the human immunodeficiency virus reservoir in patients receiving antiretroviral therapy.

Clin Infect Dis 68 8 — Serrano-Villar S, Gutiérrez C, Vallejo A, Hernández-Novoa B, Díaz L, Abad Fernández M, et al. J Infect 66 1 — Owen RE, Heitman JW, Hirschkorn DF, Lanteri MC, Biswas HH, Martin JN, et al. AIDS 24 8 — Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al.

J Infect Dis 10 — Li J, Huang HH, Tu B, Zhou MJ, Hu W, Fu YL, et al. Lee SA, Sinclair E, Hatano H, Hsue PY, Epling L, Hecht FM, et al. PloS One 9 2 :e Fischer K, Voelkl S, Heymann J, Przybylski GK, Mondal K, Laumer M, et al. Blood 7 — Paul S, Shilpi, Lal G. Role of gamma-delta γδ T cells in autoimmunity.

J Leukoc Biol 97 2 — Wu Z, Zheng Y, Sheng J, Han Y, Yang Y, Pan H, et al. Yang L, Zhu Y, Tian D, Wang S, Guo J, Sun G, et al. Transcriptome landscape of double negative T cells by single-cell RNA sequencing. J Autoimmun Petitjean G, Chevalier MF, Tibaoui F, Didier C, Manea ME, Liovat AS, et al.

Level of double negative T cells, which produce TGF-β and IL, predicts CD8 T-cell activation in primary HIV-1 infection. AIDS 26 2 — Vinton C, Klatt NR, Harris LD, Briant JA, Sanders-Beer BE, Herbert R, et al.

CD4-like immunological function by CD4- T cells in multiple natural hosts of simian immunodeficiency virus. J Virol 85 17 —8. Milush JM, Mir KD, Sundaravaradan V, Gordon SN, Engram J, Cano CA, et al. J Clin Invest 3 — Merims S, Li X, Joe B, Dokouhaki P, Han M, Childs RW, et al. Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.

Leukemia 25 9 — Fang L, Ly D, Wang SS, Lee JB, Kang H, Xu H, et al. Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. J Exp Clin Cancer Res 38 1 Sundaravaradan V, Mir KD, Sodora DL.

Curr Opin HIV AIDS 7 2 — Wang X, Zhang L, Du J, Wei Y, Wang D, Song C, et al. Caligiuri MA. Human natural killer cells. Blood 3 —9. Crinier A, Narni-Mancinelli E, Ugolini S, Vivier E. Snapshot: natural killer cells. Cell 6 —. Campos C, Pera A, Sanchez-Correa B, Alonso C, Lopez-Fernandez I, Morgado S, et al.

Effect of age and CMV on NK cell subpopulations. Exp Gerontol —7. Sun Y, Zhou J, Jiang Y. Negative regulation and protective function of natural killer cells in HIV infection: two sides of a coin.

Bayigga L, Nabatanzi R, Sekiziyivu PN, Mayanja-Kizza H, Kamya MR, Kambugu A, et al. BMC Immunol Giuliani E, Vassena L, Di Cesare S, Malagnino V, Desimio MG, Andreoni M, et al.

Immunol Lett — Luo Z, Li Z, Martin L, Hu Z, Wu H, Wan Z, et al. PloS One 12 1 :e Zhang QY, Zhang X, Su B, Liu LF, Yang XD, Tang B, et al. Chin Med J Engl 24 — Qian F, Hu S, Zhu Y, Wang Y, Liu J, Qiao J, et al.

CD56 dim NK cell is an important factor in T cell depletion of cART-treated AIDS patients. Int J Gen Med — Seifert M, Küppers R. Human memory b cells. Leukemia 30 12 — Moir S, Fauci AS. B-cell responses to HIV infection. Liu Y, Li Z, Lu X, Kuang YQ, Kong D, Zhang X, et al.

Dysregulation of memory b cells and circulating T follicular helper cells is a predictor of poor immune recovery in HIV-infected patients on antiretroviral therapy. J Med Virol 95 2 :e Lu X, Zhang X, Cheung AKL, Moog C, Xia H, Li Z, et al. Abnormal shift in b memory cell profile is associated with the expansion of circulating T follicular helper cells via icos signaling during acute HIV-1 infection.

Jia J, Zhao Y, Yang JQ, Lu DF, Zhang XL, Mao JH, et al. Naïve b cells with low differentiation improve the immune reconstitution of HIV-infected patients.

iScience 25 12 Merino KM, Allers C, Didier ES, Kuroda MJ. Stiksrud B, Aass HCD, Lorvik KB, Ueland T, Trøseid M, Dyrhol-Riise AM. AIDS 33 7 — Nabatanzi R, Cose S, Joloba M, Jones SR, Nakanjako D. Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells.

AIDS Res Ther 15 1 Altfeld M, Gale M Jr. Innate immunity against HIV-1 infection. Nat Immunol 16 6 — Rustagi A, Gale M Jr. Innate antiviral immune signaling, viral evasion and modulation by HIV J Mol Biol 6 — Gao D, Wu J, Wu YT, Du F, Aroh C, Yan N, et al. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses.

Science —6. Jakobsen MR, Bak RO, Andersen A, Berg RK, Jensen SB, Tengchuan J, et al. IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. Shi Y, Su J, Chen R, Wei W, Yuan Z, Chen X, et al.

The role of innate immunity in natural elite controllers of HIV-1 infection. Lin SC, Lo YC, Wu H. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors.

Nat Immunol 11 5 — Ting JP, Duncan JA, Lei Y. How the noninflammasome NLRs function in the innate immune system. Science — Kufer TA, Sansonetti PJ.

NLR functions beyond pathogen recognition. Nat Immunol 12 2 —8. Loo YM, Gale M Jr. Immune signaling by RIG-i-like receptors. Immunity 34 5 — Yoshimura A, Ito M, Chikuma S, Akanuma T, Nakatsukasa H.

Negative regulation of cytokine signaling in immunity. Cold Spring Harb Perspect Biol 10 7 :a Erikstrup C, Kronborg G, Lohse N, Ostrowski SR, Gerstoft J, Ullum H. T-Cell dysfunction in HIVinfected patients with impaired recovery of CD4 cells despite suppression of viral replication.

J Acquir Immune Defic Syndr 53 3 — Huang W, August A. The signaling symphony: T cell receptor tunes cytokine-mediated T cell differentiation. J Leukoc Biol 97 3 — Shaw DM, Merien F, Braakhuis A, Dulson D.

T-Cells and their cytokine production: the anti-inflammatory and immunosuppressive effects of strenuous exercise. Cytokine — Matsuzaki G, Umemura M.

Interleukin family cytokines in protective immunity against infections: role of hematopoietic cell-derived and non-hematopoietic cell-derived interleukins.

Microbiol Immunol 62 1 :1— Sabbatini F, Bandera A, Ferrario G, Trabattoni D, Marchetti G, Franzetti F, et al. Qualitative immune modulation by interleukin-2 IL-2 adjuvant therapy in immunological non responder HIV-infected patients.

PloS One 5 11 :e Schluns KS, Kieper WC, Jameson SC, Lefrançois L. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells. X Facebook LinkedIn. This Issue. Citations View Metrics. Share X Facebook Email LinkedIn. William G.

Powderly, MD ; Alan Landay, PhD ; Michael M. Lederman, MD. visual abstract icon Visual Abstract. Access through your institution. Add or change institution. Read More About HIV Infectious Diseases.

Kitano H. Biological robustness. Nat Rev Genet — Stelling J, Sauer U, Szallasi Z, Doyle FJ, Doyle J. Robustness of cellular functions. Cell — Cannon WB. Organization for physiological homeostasis. Physiol Rev — Kourilsky P. The natural defense system and the normative self model.

FRes Pradeu T. The Limits of the Self: Immunology and Biological Identity. New York, NY: Oxford University Press Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration.

Nature — Eming SA, Martin P, Tomic-Canic M. Wound repair and regeneration: mechanisms, signaling, and translation. Sci Transl Med sr6. Cordeiro JV, Jacinto A. The role of transcription-independent damage signals in the initiation of epithelial wound healing.

Nat Rev Mol Cell Biol — CrossRef Full Text Google Scholar. Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell — Karin M, Clevers H.

Reparative inflammation takes charge of tissue regeneration. White ES, Mantovani AR. Inflammation, wound repair, and fibrosis: reassessing the spectrum of tissue injury and resolution.

J Pathol —4. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med — Chizzolini C, Brembilla NC, Montanari E, Truchetet M-E. Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev — Longaker MT, Gurtner GC.

Introduction: wound repair. Semin Cell Dev Biol Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med —9. Tumors: wounds that do not heal — redux.

Cancer Immunol Res — Chovatiya R, Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol Cell —8. Clark WR. In Defense of Self: How the Immune System Really Works. Oxford; New York, NY: Oxford University Press Criscitiello MF, de Figueiredo P.

Fifty shades of immune defense. PLoS Pathog 9:e Janeway CA. How the immune system protects the host from infection. Microbes Infect — Lemaitre B, Hoffmann J. The host defense of Drosophila melanogaster.

Annu Rev Immunol — Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A special population of regulatory T cells potentiates muscle repair.

Leoni G, Neumann P-A, Sumagin R, Denning TL, Nusrat A. Wound repair: role of immune-epithelial interactions.

Mucosal Immunol — Wynn TA, Vannella KM. Macrophages in tissue repair, regeneration, and fibrosis. Immunity — Barbul A. Immune aspects of wound repair.

Clin Plast Surg — PubMed Abstract Google Scholar. DiPietro LA. Wound healing: the role of the macrophage and other immune cells. Shock — Park JE, Barbul A. Understanding the role of immune regulation in wound healing. Am J Surg S—6S. Stramer BM, Mori R, Martin P.

The inflammation-fibrosis link? A Jekyll and Hyde role for blood cells during wound repair. J Invest Dermatol — Galliot B, Crescenzi M, Jacinto A, Tajbakhsh S.

Trends in tissue repair and regeneration. Development — Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils.

Nat Immunol — Chang-Panesso M, Humphreys BD. Cellular plasticity in kidney injury and repair. Nat Rev Nephrol — Das A, Sinha M, Datta S, Abas M, Chaffee S, Sen CK, et al.

Monocyte and macrophage plasticity in tissue repair and regeneration. Am J Pathol — Plikus MV, Guerrero-Juarez CF, Ito M, Li YR, Dedhia PH, Zheng Y, et al. Regeneration of fat cells from myofibroblasts during wound healing.

Science — Silverstein SC, Rabadan R. How many neutrophils are enough redux, redux? J Clin Invest —9. Pillay J, den Braber I, Vrisekoop N, Kwast LM, de Boer RJ, Borghans JAM, et al. In vivo labeling with 2H 2 O reveals a human neutrophil lifespan of 5.

Blood —7. Silvestre-Roig C, Hidalgo A, Soehnlein O. Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood — Yang F, Feng C, Zhang X, Lu J, Zhao Y. The diverse biological functions of neutrophils, beyond the defense against infections.

Inflammation — Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol —9. Schauer C, Janko C, Munoz LE, Zhao Y, Kienhöfer D, Frey B, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines.

Nat Med —7. Sugimoto MA, Vago JP, Teixeira MM, Sousa LP. Annexin A1 and the resolution of inflammation: modulation of neutrophil recruitment, apoptosis, and clearance. J Immunol Res Gobbetti T, Cooray SN. Annexin A1 and resolution of inflammation: tissue repairing properties and signalling signature.

Biol Chem — Jones HR, Robb CT, Perretti M, Rossi AG. The role of neutrophils in inflammation resolution. Semin Immunol — Balta E, Stopp J, Castelletti L, Kirchgessner H, Samstag Y, Wabnitz GH. Methods — Takashima A, Yao Y. Neutrophil plasticity: acquisition of phenotype and functionality of antigen-presenting cell.

J Leukoc Biol — Matsushima H, Geng S, Lu R, Okamoto T, Yao Y, Mayuzumi N, et al. Neutrophil differentiation into a unique hybrid population exhibiting dual phenotype and functionality of neutrophils and dendritic cells.

Hampton HR, Chtanova T. The lymph node neutrophil. Vono M, Lin A, Norrby-Teglund A, Koup RA, Liang F, Loré K. Blood Iking-Konert C, Ostendorf B, Sander O, Jost M, Wagner C, Joosten L, et al.

Transdifferentiation of polymorphonuclear neutrophils to dendritic-like cells at the site of inflammation in rheumatoid arthritis: evidence for activation by T cells. Ann Rheum Dis — Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis.

Semin Liver Dis — Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair.

J Clin Invest — Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo J-L, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions.

J Exp Med — Wynn TA, Barron L, Thompson RW, Madala SK, Wilson MS, Cheever AW, et al. Quantitative assessment of macrophage functions in repair and fibrosis.